Last reviewed · How we verify
Comparator: valdecoxib
Valdecoxib selectively inhibits cyclooxygenase-2 (COX-2), reducing prostaglandin production to decrease inflammation and pain.
Valdecoxib selectively inhibits cyclooxygenase-2 (COX-2), reducing prostaglandin production to decrease inflammation and pain. Used for Osteoarthritis, Rheumatoid arthritis, Acute pain.
At a glance
| Generic name | Comparator: valdecoxib |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Selective COX-2 inhibitor (coxib) |
| Target | COX-2 (Cyclooxygenase-2) |
| Modality | Small molecule |
| Therapeutic area | Rheumatology / Pain Management |
| Phase | Phase 3 |
Mechanism of action
As a selective COX-2 inhibitor, valdecoxib preferentially blocks COX-2 enzyme activity over COX-1, thereby reducing inflammatory prostaglandins while theoretically sparing the protective prostaglandins produced by COX-1 in the gastrointestinal tract and platelets. This selectivity was intended to provide anti-inflammatory and analgesic benefits with a reduced risk of gastrointestinal ulceration compared to non-selective NSAIDs.
Approved indications
- Osteoarthritis
- Rheumatoid arthritis
- Acute pain
- Dysmenorrhea
Common side effects
- Hypertension
- Edema
- Dyspepsia
- Headache
- Cardiovascular events
Key clinical trials
- Predicting Patients' Response to Spinal Manipulation (NA)
- A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-190)(COMPLETED) (PHASE3)
- A Study of Two Approved Drugs in the Treatment of Postoperative Dental Pain (0966-181)(COMPLETED) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |